Table 1 Clinicopathological characteristics of cohorts A and triple-negative breast cancer cohort B
Parameter | Cohort A | Cohort B (TNBC) |
|---|---|---|
N (%) | N (%) | |
All patients | 398 | 156 |
Age, years | ||
  <50 | 124 (31.2) | 72 (46.15) |
  ≥50 | 257 (64.6) | 80 (50.1) |
 Unknown | 17 (4.3) | 4 (2.56) |
Nodal status | ||
 Positive | 78 (19.6) | 15 (9.6) |
 Negative | 203 (51.0) | 39 (25) |
 Unknown | 117 (29.4) | 104 (66.6) |
Tumor size | ||
  <2 cm | 217 (54.5) | 44 (28.2) |
 2–5 cm | 73 (17.3) | 74 (47.43) |
 Unknown | 108 (27) | 38 (24.35) |
Grade | ||
 1–2 | 97 (24.37) | 45 (28.84) |
 3 | 103 (25.87) | 78 (50.00) |
 NA/Unknown | 198 (49.7) | 32 (2) |
ERα | ||
 Positive (1–3) | 264 (66.3) |  |
 Negative (0) | 89 (22.3) |  |
 Unknown | 45 (11.3) |  |
HER2 | ||
 Positive (3+) | 20 (5) |  |
 Negative (0–1+) | 272 (68.3) |  |
 Unknown/Equivocal | 106 (26.6) |  |
Adjuvant treatment | ||
 Hormonal only | 93 (23.4) |  |
 Chemotherapy only | 72 (18.1) |  |
 Hormonal+Chemo | 48 (12.1) |  |
 None | 89 (22.4) |  |
 Unknown | 96 (24.1) |  |
Follow-up (m) | ||
 Median (range) | 139 (3–385) | 52 (4–231) |